# Teva Settles Multistate Drug Pricing Suit

Teva Pharmaceutical Industries Ltd. and its Actavis subsidiary reached an agreement in principle to settle claims in a generic-drug price-fixing case brought by attorneys general from more than 40 states. The settlement terms were not disclosed, and the federal court stayed the case against Teva. The case concerns pharmaceutical market oversight rather than a government procurement or contract award, but its outcome may be relevant to public buyers assessing supplier pricing practices and market risk.

- Government healthcare buyers and contractors should distinguish the settlement from a procurement action: the signal announces no contract, funding, or solicitation opportunity.
- Pharmaceutical suppliers serving public programs may find the case relevant to pricing oversight and the legal risks associated with competition and market conduct; no specific purchasing or compliance requirement is identified in the signal.

**Jurisdictions:** sled
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** November 17, 2026

### Government Entities
- State attorneys general from more than 40 states
- U.S. District Court for the District of Connecticut

### Vendors
- Teva Pharmaceutical Industries Ltd. (Party to the settlement agreement in principle)
- Actavis (Teva subsidiary and party to the settlement agreement in principle)
